Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment

Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment

Submitted by admin on July 24, 2018 - 10:54am
Source: 
CP Wire
News Tags: 
Adaptimmune
GSK
GSK3377794
T-cells
Headline: 
Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment
snippet: 
  • GSK ‘794 is an engineered T-cell therapy using patient's own cells
  • Ptoential payments to Adaptimmune could be as much as $500 million
  • Adaptimmune as three additional TCR therapy candidates under development

Do Not Allow Advertisers to Use My Personal information